argenx stock in focus after $1.15 billion UNP deal

argenx agreed on November 9, 2026, to acquire Unnatural Products, Inc. (UNP), adding a macrocyclic peptide discovery engine to its immunology platform. The company announced the transaction in a press release published at 07:00 CET.

Under the agreement, argenx will acquire all remaining UNP shares. The transaction consists of 550 million US dollars in upfront cash and up to 595 million US dollars in development and regulatory milestone payments, for potential total consideration of up to 1.15 billion US dollars. The boards of both companies approved the deal, which is expected to close by the end of 2026 subject to customary closing conditions.

Oral and long-acting medicines

The acquisition expands argenx's options for developing oral or long-acting medicines for people with serious immune-mediated diseases. UNP's platform combines parallel experimentation and machine learning to address medicinal chemistry challenges in macrocyclic peptides, including targets that have traditionally been difficult to drug.

argenx said the peptide capabilities complement its antibody engineering. Chief Executive Officer Karen Massey described the transaction as an investment in the company's next chapter and said the two businesses had developed a strong fit through more than two years of collaboration. The comments point to a broader research strategy alongside the company's established antibody-based programs.

After closing, UNP's team and leadership will continue operating from Santa Cruz, California, which will become argenx's base for peptide discovery. UNP will lead discovery work within a strategic framework agreed with argenx, while argenx brings clinical development and commercialization capabilities.

Execution remains the next test

The deal gives argenx access to an additional technology platform, but much of the consideration depends on future development and regulatory milestones. Investors therefore still face execution risk: the value of the transaction will depend on whether the platform produces candidates that can advance through development and eventually reach patients.

argenx stock traded at 887.60 euros on Lang & Schwarz at 10:08 CET on Thursday, November 12, 2026.

The broader Dutch market provides the immediate market context for investors following argenx and other listed companies through the AEX index.

The next major milestone is the planned transaction closing by year-end, while argenx's management is scheduled to appear at the Jefferies London Global Healthcare Conference on November 17, 2026. More news and analyses on argenx stock.